Vimta Labs Limited has informed the Exchange about Investor Presentation
Vimta Labs Limited Registered Office: 142, IDA Phase II, Cherlapally Hyderabad-500 051 ,Telangana, India T: +91 4027264141 F : +91 40 2726 3657
B S E Limited, P J Towers, Dalal Street, Mumbai: 400001. Scrip Code No.524394
VLL\SE\007\2025-26 Date: 28.04.2025
National Stock Exchange of India Limited, “Exchange Plaza”, Bandra, Kurla Complex, Bandra (E),Mumbai – 400051. Trading Symbol: VIMTALABS
Dear Sir/Madam, Sub: Investor Presentation –Q4 results – FY 2024-25 Pursuant to provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”) we are enclosing herewith the Investor Presentation. Further, pursuant to Regulation 46 of the Listing Regulations, the aforesaid information will be available on the website of the Company i.e., https://vimta.com/investor-presentation/ This is for your information and necessary records. For VIMTA LABS LTED Sujani Vasireddi
Company Secretary Attachments: as above.
Life Sciences Campus, # 5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad - 500 101, Telangana, India T : +91 40 6740 4040 E: mdoffice@vimta.com LIRL : www.vimta.com CIN : L24110TG1990PLC011977
Vimta Labs Limited
Investor Presentation Q4 & FY25
Disclaimer
The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.
This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global industries that we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.
No part of this presentation may be reproduced, quoted or circulated without prior written approval from Vimta Labs Ltd.
3
Table of Contents
Q4 & FY25 Earnings
Company Overview
Industry Landscape
Our Competitive Advantage
Way Forward
Q4 & FY25 Earnings
Q4 & FY25 Highlights FY25 Business Updates Key Metrics: Q4 & FY25 Profit & Loss Statement Financial Track Record Shareholding Pattern
Q4 FY25 Highlights
Rs 961 Mn
Total Income
Rs 347 Mn Margin 36.1% EBITDA
Rs 250 Mn
PBT
₹
Rs 8.22
EPS
Rs 39 Mn
CAPEX Outflow
Rs 183 Mn Margin 19.1% PAT
6
FY25 Highlights
Rs 3,482 Mn
Total Income
Rs 1262 Mn Margin 36.2% EBITDA
₹
Rs 30.02
EPS
Rs 791 Mn
CAPEX Outflow
Rs 890 Mn
PBT
Rs 668 Mn Margin 19.2% PAT
0.02x
Debt to Equity Ratio
Rs 85 Mn (March 31st 2025) Total Debt
Rs 329 Mn (March 31st 2025)
Cash and Cash Equivalents
7
FY25 Business Updates
•
•
•
Successful regulatory audits from various regulatory authorities: USFDA (Clinical GLP); European Medicines Agency (cGMP – human health and animal health); Turkey (cGMP); Kazakhastan (GCP), NGCMA (OECD-GLP) and CDSCO (GCP, Medical Devices).
Forayed into Clinical trial services
Food Division conferred with ‘Outstanding Laboratory Performance Award 2024‘ by CII for the 2nd consecutive year.
• Business Transfer of CRL division to Thyrocare
• Relocated Pune food testing lab to Nashik with a view to be closer to agri produce regions.
• Capacity expansion: At Life Sciences Facility, added an additional ~200,000 sft of modern laboratory spaces
•
EMTAC is merged with Vimta: Scheme has been sanctioned by NCLT Hyderabad bench.
8
Key Metrics: Q4 FY25
Total Income (In ₹ Mn)
EBIDTA & EBIDTA Margin (In ₹ Mn, %)
PAT & PAT Margin (In ₹ Mn, %)
Basic EPS (In ₹)
EBIDTA
EBIDTA Margin
PAT
PAT Margin
31.4% YoY
31.9% YoY
36.0%
37.6%
36.1%
731
911
961
263
343
347
31.2% YoY
19.2%
19.1% 140
175
19.1% 183
200
175
150
125
100
75
50
25
-
19%
19%
19%
19%
19%
19%
19%
19%
19%
19%
5
0
6.3
7.9
8.2
Q4FY24
Q3FY25
Q4FY25
Q4FY24 Q3FY25 Q4FY25
Q4FY24 Q3FY25 Q4FY25
Q4FY24 Q3FY25 Q4FY25
9
Key Metrics: FY25
Total Income (In ₹ Mn)
EBIDTA & EBIDTA Margin (In ₹ Mn, %)
PAT & PAT Margin (In ₹ Mn, %)
Basic EPS (In ₹)
EBIDTA
EBIDTA Margin
PAT
PAT Margin
19.1% YoY
29.1% YoY
33.4%
36.2%
2,923
FY24
3,482
FY25
977
FY24
1,262
FY25
725
700
675
650
625
600
575
550
525
500
475
450
425
400
375
350
325
300
275
250
225
200
175
150
125
100
75
50
25
-
36.8% YoY
16.7%
488
FY24
20%
19%
19%
18%
18%
17%
17%
16%
16%
15%
19.2%
668
FY25
22.0
FY24
30.0
FY25
10
Financial Track Record
TOTAL INCOME (₹ Mn)
PROFITABILITY (₹ Mn)
EBITDA & EBITDA Margin
PAT & PAT Margin
1,837 2,115 2,797 3,216 2,923 3,482
11.2% CAGR
29%
31%
33%
36%
25%
18%
330
538
817
984
977
1,262
19%
17%
15% 15%
25.1% CAGR
4%
68
10%
214
413
482 488 668
46.3% CAGR
FY20
FY21
FY22
FY23
FY24
FY25
FY20
FY21
FY22
FY23
FY24
FY25
FY20
FY21
FY22
FY23
FY24
FY25
Total Revenue
EBIDTA
EBIDTA Margin
PAT
PAT Margin
RoE (%)
RoCE (%)
Debt to Equity
Total Capex
BALANCE SHEET RATIOS
4%
11%
18%
17%
15%
18%
15% 18% 25% 22% 19% 23%
FY20
FY21
FY22
FY23
FY24
FY25
FY20
FY21
FY22
FY23
FY24
FY25
0.2
0.1
0.0
0.16
0.16 0.08 0.05 0.06 0.02
166
357
450
492
763
791
FY20 FY21 FY22 FY23 FY24 FY25
FY20
FY21
FY22
FY23
FY24
FY25
a. b.
Financial numbers for the period FY24 & FY25 are from continuing operations and exclude Diagnostic and Pathological services business CAGR for the period FY20-FY25
11
Profit & Loss Statement
Particulars (₹ Mn)
Revenue from Operations
Other Income
Total Income
Material and Testing Costs
Cost of lab setup
Changes in inventories of work-in-progress
Employee benefits expense
Other expenses
Total Expenses
EBIDTA
EBIDTA (%)
Finance costs
Depreciation expense
Profit before tax
PBT (%)
Tax
Profit for the year
PAT (%)
Basic EPS (INR)
Q4 FY25
Q4 FY24
YoY (%) Q3 FY25
QoQ(%)
944.4
16.4
960.8
181.6
0.2
0.0
272.6
159.6
614.1
346.8
727.3
3.8
731.2
132.9
0.2
0.6
214.9
119.6
468.2
263.0
36.1%
36.0%
4.4
92.1
250.3
26.0%
67.1
183.2
19.1%
8.2
5.3
78.4
179.4
24.5%
39.8
139.6
19.1%
6.3
899.0
12.0
911.0
204.0
2.0
0.0
234.0
128.0
568.0
343.0
37.6%
6.0
98.0
239.0
26.2%
64.0
175.0
19.2%
7.9
31.4%
31.9%
39.5%
31.2%
30.3%
5.5%
1.1%
4.7%
4.7%
4.1%
FY25
3,439.8
42.4
3,482.2
710.2
4.3
0.0
970.2
535.7
2,220.3
1,261.9
36.2%
19.0
352.9
890.0
25.6%
222.5
667.5
19.2%
30.0
FY24
YoY (%)
2,886.0
37.1
2,923.1
19.1%
573.2
2.4
1.0
891.8
477.2
1,945.6
977.5
33.4%
21.0
331.4
625.0
21.4%
136.9
488.1
16.7%
22.0
29.1%
42.4%
36.8%
36.2%
12
Shareholding Pattern
Shareholding as on 31st March 2025
Others 58.2%
Promoters 36.7%
DII 1.4%
FII 3.7%
Source: NSE & BSE
#Cash and Cash equivalents includes other bank balances
Share Information as on 31st March 2025
NSE Ticker
BSE Ticker
Market Cap (INR Cr)
% free-float
Free-float market cap (INR Cr)
Total Debt (INR Mn)
Cash & Cash Equivalents (INR Mn)
Shares Outstanding
3M ADTV (Shares)*
3M ADTV (INR Cr)*
Industry
VIMTALABS
524394
2,223.67
63.30%
1,407.57
85
329
2,22,34,512
1,89,397
18.62
TIC
13
Company Overview
Vimta at a Glance Our Journey Services Geographical Presence Management
Vimta at a Glance
Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high- quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, small molecules, agro-chemicals, food & beverages, electronics, medical devices, home and personal care products, and environment testing.
1,300+ Dedicated Multi-Disciplinary Team
10 Labs and Offices across India
40+ Years Of experience in CRTO industry
600,000+ Sq. Ft. of Ultra-modern lab spaces
90+ Successful Regulatory Audits
15
Our Journey
Infrastructure
People
Investment
Capabilities
2024
600,000+ ft2
1300+
492 M
2015
400,000+ ft2
1000+
580 M
Pharma & Biopharma: Discovery & development services; Food; Environment; Electronics Testing
Analytical – Pharma, Biopharma & Food; Clinical Research; Preclinical; Clinical Diagnostics; Environment Testing
Revenue s
3,216 M
1,073 M
2006
1992
200,000+ ft2
600+
992 M
Clinical Research; Environment; Analytical Testing – Food & Pharma
542 M
50,000+ ft2
150+
85 M
Environment; Analytical – Food & Pharma; Toxicology; Material testing; Clinical Research
16 M
1984
500 ft2
6
200,000
Minerals & ores; Metals; Rice bran oil testing
156,000
• •
Investment & Revenues in INR Investments depicted may have spread across more than the denoted year
16
Our offerings
Drug discovery and development services
Food & Agri Testing
Electronics & Electricals Testing
Environment Testing & Consultancy
17
1. Drug discovery and development services
Offerings
Industry
Pharma Analytical
Clinical Research
Preclinical Research
Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health.
Pharmaceuticals, Biologics, Medical Device, Agrochemical, Speciality Chemicals
Accreditations & Regulatory Approvals
DCA, USFDA, WHO, EMA, DRAs of Ukraine, Turkey
CDSCO, USFDA, WHO, MHRA, NPRA, and European DRAs
OECD-GLP, CCSEA, DSIR, AAALAC
Wide range of analytical services E&L studies Stability testing Method
Microbiology Immunogenecity
studies
Characterization Bioassays
Services
development
Validations Genotoxic impurities
Elemental analysis In vitro studies Physical
Characterisation Dissolution Testing
▪ BA/BE Studies ▪ Bioanalytical ▪ Clinical Trials (Phase I to IV) ▪ Clinical End Point Studies ▪ Claim Studies
Comprehensive in vitro, ex vivo and in
vivo studies ADME, and PK IND enabling packages (genetic
toxicology, safety pharmacology, general toxicology, & toxicokinetic studies).
Chronic toxicology, reproductive
toxicology, neurotoxicology, immunotoxicology, and carcinogenicity
Biowaiver and alternative to animal
studies
Ecotoxicology, environmental fate and
metabolism studies
18
2. Food & Agri Testing
Industry
Food Manufacturing & Processing, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed
No. of Locations
7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida)
Accreditations & Regulatory Approvals
• FSSAI, ISO 17025, BIS, APEDA, EIS, SHEFEXIL, EU Commission, OCED-GLP, AGMARK, Tea Board, Spices Board • Hyderabad Lab is a National Reference Lab for Water & Beverages Testing • Mumbai Lab is a National Food Laboratory, operated for FSSAI
Services
Food contaminants, food allergens, microbiology/pathogen, GMO testing, nutrition & composition analysis for all
agri, food, food products, water and beverages New product development support, validations Shelf life assessments Packaging material testing Nutraceuticals testing, method validations Animal feed analysis Argo-chemical (crop sciences): support for research and development, method development, validation and
testing for regulatory submissions in India, Europe, South America, Japan, South East Asia
19
3. Electricals & Electronics Testing & Certification
Industry
Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries
No. of Laboratories
Accreditations & Regulatory Approvals
Services
1 (Hyderabad)
ISO 17025, TEC BIS & NABCB (of Emtac Laboratories Pvt Ltd., fully owned subsidiary)
EMI/EMC testing Radio Frequency testing Environmental & reliability testing Mechanical & electrical safety testing Performance testing Product Certification CE marking
20
4. Environment Testing & Consultancy Services
Industry
No. of Locations
Accreditations & Regulatory Approvals
Services
Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc.
4 (Hyderabad, Chennai, Kolkata and Noida)
MoEF, ISO 17025, QCI/NABET, OSHAS 45000
Post project monitoring Industrial hygiene & Indoor air Advanced testing & tailor-made services (CEMS validation, PG for pollution equipment, Dioxins, Furans,
Industrial Gas, VOC as per LEED and EPA)
Offshore monitoring SIA & hydrogeological studies EHS audits, Hazardous waste study, Life cycle assessment Due diligence studies Green audit, Metrological studies Noise, air, traffic modelling etc.
21
Geographical Presence
Hyderabad (Headquarters)
Food
Pharma
Electronics & Electrical
Environment
Food
Environment
Hyderabad
Chennai
Noida
Kolkata
Hyderabad
Ahmedabad
Noida
Mumbai (NFL)
Nashik
Bengaluru
Nellore
Electrical and Electronics
Hyderabad
22
Key Management Team
S P Vasireddi Executive Chairman
Harita Vasireddi Managing Director
Sreenivas Neerukonda Executive Director
Siva Kambhampati Chief Financial Officer
Harriman Vungal Executive Director - Operations
Dr. S P Vasireddi is a Scientist – Technocrat – Entrepreneur having more than 45 years of experience in contract research and testing laboratory management. He is the founder and Chairman of VIMTA.
Dr. Vasireddi is reckoned as the pioneer of CRO industry in India. He led VIMTA from a single bench laboratory to a wide spectrum, globally recognized CRTO. In recognition of his eminence in CRO & Testing industry he is/has been nominated as a member on the Advisory/ Governing Boards of several apex scientific and regulatory bodies of the country such as FSSAI, NABL etc.
Harita has close to 25 years of experience in the TIC/CRO industry with track record of growth and profitability.
include Her Core competencies driving management organizational and development, quality management systems, and risk management.
adaptability
&
She holds an MBA in Operations Management from Boston College, USA; and is a B.Pharm graduate from Mysore university, India
Sreenivas’s core competencies include strategic planning and execution, new service opportunities development, communication and relationship building, competitive intelligence, and fostering strong team relations to deliver goal-oriented performance.
He holds an MBA in Management Information Systems, University of Oklahoma, USA; B.Pharm, Nagpur University, India.
Siva is a seasoned finance professional with a strong academic foundation. He is a CA and secured 63rd rank in cost accountancy. With over 16 years on experience in the engineering and pharmaceutical industries, he brings diverse expertise in strategic financial planning & management, product costing & pricing, and treasury management.
He has previously worked at Artson engineering Ltd. (A TATA Enterprise), Hyderabad as a CFO.
Harriman was inducted to the Board as one of the Promoter Directors in 1990 and was appointed as Technical Director of the Company in 1992. He has extensive lab operations management experience and is a go to senior resource on GXPs.
He has led the Company’s effort in building state of the art IT infrastructure, systems and their compliance to applicable regulations.
He holds D. Tech in Electronics from Toronto, Canada.
23
Industry Landscape
Market Opportunity Factors Driving Industry Growth
Markets Opportunity
Pharmaceutical & Biopharmaceuticals
Preclinical
Food Testing
Environment Testing
Electronics Testing
957.6
127.3
40.5
20.2
l a b o G
l
)
n B D S U
(
405.5
76.6
19.5
11.1
13.4
6.8
2020 | 2028
2023 | 2028
2022 | 2032
2022 | 2030
2021 | 2031
25
Markets Opportunity
Pharmaceutical & Biopharmaceuticals
Preclinical
Food Testing
Environment Testing
Electronics Testing
130
0.9
1
0.6
0.4
13.4
42
0.5
0.2
6.8
n a i d n I
)
n B D S U
(
2021 | 2030
2021 | 2030
2022 | 2027
2021 | 2026
2021 | 2028
26
Factors Driving Industry Growth
Drug Discovery & Development
Increasing demand for new drug innovations, growth in biologics and vaccine products development, and increasing regulations in pharma and biotech industry
Specialized knowledge, skills and testing tools that CROs can provide
Food Testing
Growing international food regulations, evolving Indian food safety regulations, growing world population, and increasing demand for independent third-party inspection & testing
Electrical & Electronics Testing
Surge in demand for certification services of electrical & electronic products, growing defence budgets and make in India initiatives
Green push by Government for electrical vehicles
Environment Testing
Increase in regulations to address the growing concerns of air, water and soil contamination
27
Our Competitive Advantage
Our Position in the CRTO Landscape Our Strength
Our Position in the CRTO Landscape
Pharma Analytical
Food Testing
#1 in India
#1 in India
Customers – 90% of India top 20
36% revenues from overseas
Serving 7 of India’s top 10 food companies
The only private EU commission approved lab in India
Clinical Research
Preclinical
Among the most reputed CROs in India
Amongst Top 5 in India
75% of revenues from overseas
Electronics & Electricals
Start-up
Environment
Among top 5 in India
Customers – PSUs, large corporations across industries
29
Our Strengths
Infrastructure
Unparalleled lab infrastructure in the country. Gold LEED certified Vivarium
Customer Centricity
Long term partnerships with customers
Strong culture of quality and compliance
Compliance
Long & successful regulatory track record – cGMP, GLP, GCP
Compliance
Innovations
Strong culture of quality and compliance
Continuous addition of services and evolving excellence
Knowledge
Multi-disciplinary, knowledgeable, skilled and trained manpower
Technology
Wide range of state-of-the-art technologies and scalable capacities
30
Way Forward
Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies
Favourable markets
Core business strategies
Core operational strategies
Best practices
✓ Growth momentum
✓ Capacity expansions
in markets
✓ Growing demand for safe & quality - drugs, food, diagnostics, electronics & clean environment
✓ Service innovations
✓ Penetration into new
markets
✓ Customer partnerships
✓ Operational excellence
✓ Hiring right talent
✓ Quality & compliance
culture
✓ Cutting edge technologies
✓ Good corporate governance
✓ Risk management
✓ Listening to customers’
needs
✓ Continuous learning
We aspire to reach revenues of >Rs.500 cr by 2025/26
32 32
Thank You
Vimta Labs Ltd.
Chief Financial Officer
Siva Rama Krishna Kambhampati Siva.Kambhampati@vimta.com
Siddesh Chawan Siddesh.Chawan@in.ey.com Advait Bhadekar Advait.Bhadekar@in.ey.com
Registered Office Plot
NSE: VIMTALABS
Plot #142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051
BSE: 524394
ISIN: INE579C01029
Website: www.vimta.com
Page 33